Explanation
Eculizumab
Eculizumab isamonoclonauantibodytocomplementfactorC5 which
blockscomplement activation.Evidence suqgests thatShigatoxin
associatedUS.thediaanosishereisassociatedwithcomolement
activation.particularlv ofC3andC9.intervention with anaqentthat
blockscompement activationisthereforeloaicaLEartier intervention
witheculizumabismosteffective,andsmaustudies suaqest tsuse is
associatedwithimorovedneuroloaicat outcomes.
@1MIN NDOCRINE
